Advertisement Epistem signs supply, distribution agreement with Becton Dickinson - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Epistem signs supply, distribution agreement with Becton Dickinson

Epistem has signed supply and distribution agreement with Becton Dickinson (BD) for Mycobacterium tuberculosis (TB) test on a global basis (excluding India and the Indian Sub Continent) using its Genedrive platform.

The agreement includes an upfront payment of $1m with future milestone payments of up to $3m, alongside escalating supply volumes over the next five years.

Genedrive provides a rapid, low cost Point of Care device and aims to provide a gold standard identification of TB and antibiotic resistance testing, according to Epistem.

The Genedrive platform, which has applications across a range of bacterial, viral and fungal, and somatic mutation diseases, and TB test have received CE-IVD registration and regulatory submissions are now in preparation for the Indian market.

The World Health Organisation has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.